Depression can make every decision feel heavier than it should. When you are comparing IV ketamine and SPRAVATO®, the terminology alone can become another burden.
Both approaches have drawn attention because they differ from conventional antidepressant pathways. Both require clinical judgment, medical screening, and supervised care. But they are not interchangeable. The route of administration, medication formulation, follow-up structure, and practical experience of treatment are meaningfully different.
At Invictus Clinic, we believe the first step is not choosing a label. It is having a careful conversation about your history, your current symptoms, your medications, and what support you may need around treatment. Our work begins with that kind of depression care in Marietta.
A Different Medication, Delivered Differently
IV ketamine is typically racemic ketamine, meaning it contains two mirror-image forms of the medication. In psychiatric care, IV ketamine is used off-label. That does not mean it is unstudied. It means the FDA has not approved the IV ketamine formulation specifically for psychiatric indications.
SPRAVATO® is intranasal esketamine. Esketamine is one component of racemic ketamine, delivered as a nasal spray. SPRAVATO® is FDA-approved for specific depression indications and is administered under a required risk-management program with observation after dosing. Reviews of ketamine and esketamine research describe important differences in formulation, delivery, and regulatory status, even where the underlying biology overlaps (clinical trial evidence on ketamine and esketamine (Vekhova et al., 2025)).
The delivery difference is simple on paper. IV ketamine is administered through an intravenous line in a monitored setting. SPRAVATO® is self-administered as a nasal spray while you are in a certified treatment setting, under staff supervision.
The experience is less simple. It is personal.
IV Ketamine: A Measured Infusion Visit
With IV ketamine, the medication enters the bloodstream directly. A clinician can establish a dose and, when clinically appropriate, make careful adjustments over time. An infusion appointment includes medical monitoring before, during, and after treatment.
People often ask whether IV treatment is more intense. There is no universal answer. Dose, medical history, sensitivity to medication, sleep, anxiety, and expectations can all shape the day. Some people experience temporary dissociation, changes in perception, nausea, elevated blood pressure, or fatigue. These effects are reasons monitoring matters, not a reason to assume the experience will be the same for everyone.
Guidance on racemic ketamine emphasizes appropriate patient selection, medical assessment, vital-sign monitoring, and plans for follow-up rather than a one-size-fits-all protocol (recommendations for IV ketamine monitoring (Swainson et al., 2021)). This is the standard we take seriously in our Marietta ketamine clinic.
You will need a ride home. You should not drive after an IV ketamine infusion.
SPRAVATO®: A Structured Nasal-Spray Setting
SPRAVATO® visits are structured differently. You administer the nasal spray yourself under supervision, then remain at the treatment site for monitoring. The observation period is an essential part of treatment, given the possibility of sedation, dissociation, blood-pressure changes, and impaired attention after dosing.
SPRAVATO® is commonly used alongside an oral antidepressant in certain treatment-resistant depression circumstances, although evidence has also continued to examine its use in other defined clinical settings. In one randomized trial, intranasal esketamine added to an oral antidepressant showed benefit for some adults with treatment-resistant depression (a trial of esketamine with oral antidepressants (Daly et al., 2018)).
That finding does not determine whether it is right for you. A study population is not a person sitting across from us. Your medication history, medical conditions, substance-use history, blood pressure, support system, and treatment goals all deserve attention.
You should arrange transportation after SPRAVATO® treatment. You should not drive or operate machinery until the next day after a restful sleep. The day needs room around it.
What the Research Can and Cannot Compare
It is tempting to ask which option works better. We understand the question. It deserves an honest answer.
Both IV ketamine and intranasal esketamine have evidence supporting antidepressant effects for some people, particularly in treatment-resistant depression. Yet direct comparisons remain limited, and the studies do not erase meaningful differences in dosing, study design, eligibility criteria, and treatment context. A systematic review and meta-analysis comparing the two approaches found evidence of benefit, while also underscoring the need for better comparative research (comparative evidence across IV and intranasal treatment (Seshadri et al., 2024)).
Response is not a character test. It is not proof that you tried hard enough, either. Depression is complex, and treatment planning should leave room for adjustment.
We may discuss your broader options, including conventional medication management, psychotherapy, lifestyle supports, and the different approaches to depression. The right next step is often clearer after a full evaluation.
Monitoring Is Part of the Treatment
Monitoring is not an administrative detail. It is part of safe care.
For either option, we consider factors such as:
Your depression history and previous medication trials
Current prescriptions, supplements, and substance use
Blood pressure and relevant medical conditions
Past reactions to anesthesia or dissociative medications
Pregnancy considerations where applicable
Your ability to arrange transportation and post-visit support
Whether symptoms include thoughts of self-harm or urgent safety concerns
Medication treatment requires attention to side effects, interactions, and changes over time. Contemporary psychiatric dosing guidance supports ongoing assessment rather than treating a prescription or infusion as a standalone event (principles of psychotropic monitoring (DeBattista et al., 2024)).
For us, the question is never simply, “Can we provide this?” It is, “Does this fit your clinical picture, and can we provide the supervision it requires?”
Questions Worth Bringing to Your Consultation
A good consultation should make room for your questions. You do not need to arrive with perfect language. Still, these may help:
Is my depression considered treatment-resistant, and how are you defining that?
Why might IV ketamine or SPRAVATO® be considered in my situation?
What medications would need to be reviewed before treatment?
What monitoring happens during and after each visit?
What side effects should my family or support person understand?
How will we decide whether treatment is helping?
What happens if my symptoms worsen between appointments?
How does treatment fit with therapy and my existing psychiatric care?
We also encourage openness about substance-use concerns. Ketamine has misuse potential outside of clinical supervision, and that history belongs in a thoughtful treatment conversation. You can learn more about the importance of integrated support through our addiction treatment services.
Frequently Asked Questions
Is IV ketamine the same as SPRAVATO®?
No. IV ketamine generally uses racemic ketamine delivered through an infusion. SPRAVATO® uses esketamine, delivered as a nasal spray in a supervised setting. Their related chemistry does not make their treatment models identical.
Is IV ketamine FDA-approved for depression?
IV ketamine is used off-label for psychiatric conditions, including depression. SPRAVATO® is FDA-approved for specific depression indications. A consultation should clarify what those distinctions mean for your circumstances.
Does one option work faster?
Some research has reported relatively rapid antidepressant effects with ketamine-based treatments for some participants. Timing, degree of change, and durability vary. A broad review of ketamine for depression describes this potential while emphasizing the limits of individual prediction (evidence on ketamine’s antidepressant effects (Yavi et al., 2022)).
Can I drive home afterward?
After IV ketamine, you should arrange a ride home and should not drive after your infusion. After SPRAVATO® treatment, you should arrange transportation and should not drive or operate machinery until the next day after a restful sleep.
How do I know which conversation to start with?
Start with your full history. We can discuss IV ketamine, SPRAVATO®, and other appropriate paths without forcing a quick decision. If you are ready to talk through ketamine treatment for depression or other supervised options, we invite you to contact Invictus Clinic at 770-580-1042 or schedule a consultation.
This article is educational and is not medical advice. If you are in immediate danger, have thoughts of self-harm, or need urgent emotional support, call or text the 988 Suicide and Crisis Lifeline at 988.
Works Cited
1. Vekhova KA, et al. Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations. https://pubmed.ncbi.nlm.nih.gov/39428602/
2. Swainson J, et al. The Canadian Network for Mood and Anxiety Treatments Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder. https://pubmed.ncbi.nlm.nih.gov/33174760/
3. Daly EJ, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/29282469/
4. Seshadri A, et al. Efficacy of Intravenous Ketamine and Intranasal Esketamine With Dose Escalation for Major Depression: A Systematic Review and Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/38537759/
5. DeBattista C, et al. The Black Book of Psychotropic Dosing and Monitoring. https://pubmed.ncbi.nlm.nih.gov/38993656/
6. Yavi M, et al. Ketamine Treatment for Depression: A Review. https://pubmed.ncbi.nlm.nih.gov/35509843/
Disclaimer
This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.
